Tuesday, 29 November 2022


Singapore grants interim authorisation for first bivalent COVID-19 booster vaccine

14 September 2022 | News

Omicron-targeting bivalent booster candidate, mRNA-1273.214 (Spikevax) poised to be the next-generation vaccine offering a superior breadth of an immune response against Omicron BA.4 and BA.5

Photo Credit: Freepik

Photo Credit: Freepik

Singapore Health Sciences Authority (HSA) has granted an interim authorisation for the use of Moderna’s Omicron-targeting bivalent booster vaccine. Also refered as Spikevax Bivalent Original/Omicron (mRNA-1273.214) is ahead in the race for active immunization to prevent COVID-19 disease in individuals 18 years of age and older.

Spikevax Bivalent Original/Omicron is a next-generation bivalent vaccine that contains 25 µg of mRNA-1273 (Spikevax) and 25 µg of a vaccine candidate targeting the Omicron variant of concern (BA.1).

The Phase 2/3 Clinical trial data indicates mRNA-1273.214 proven for a superior neutralizing antibody response against Omicron (BA.1) when compared to the currently authorized 50 µg booster dose of Spikevax (mRNA-1273) in baseline seronegative participants.

Spikevax Bivalent Original/Omicron (mRNA-1273.214) elicited higher neutralizing antibody titers against the Omicron subvariants BA.4 and BA.5 when compared to Spikevax (mRNA-1273).

Moderna is working with the HSA and the Government of Singapore to make Spikevax Bivalent Original/Omicron available to people in Singapore during September. Moderna has received authorization decisions for omicron-targeting bivalent boosters in the United States, Australia, Canada, Europe, Japan, South Korea, Switzerland, Taiwan, and the UK to date and has completed regulatory submissions worldwide.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account